BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17724065)

  • 1. The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals.
    Lee SJ; Lee SS; Jeong HE; Shon JH; Ryu JY; Sunwoo YE; Liu KH; Kang W; Park YJ; Shin CM; Shin JG
    Drug Metab Dispos; 2007 Nov; 35(11):2095-101. PubMed ID: 17724065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
    Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
    Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
    Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
    Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.
    Eap CB; Buclin T; Hustert E; Bleiber G; Golay KP; Aubert AC; Baumann P; Telenti A; Kerb R
    Eur J Clin Pharmacol; 2004 Jun; 60(4):231-6. PubMed ID: 15114431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
    Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
    Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
    Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
    Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
    He P; Court MH; Greenblatt DJ; Von Moltke LL
    Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.
    Shih PS; Huang JD
    Drug Metab Dispos; 2002 Dec; 30(12):1491-6. PubMed ID: 12433824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
    Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
    Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
    Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing midazolam hydroxylation activity in human liver microsomes.
    He P; Court MH; Greenblatt DJ; von Moltke LL
    Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine.
    Maekawa K; Yoshimura T; Saito Y; Fujimura Y; Aohara F; Emoto C; Iwasaki K; Hanioka N; Narimatsu S; Niwa T; Sawada J
    Xenobiotica; 2009 Feb; 39(2):140-7. PubMed ID: 19255940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.
    Miao J; Jin Y; Marunde RL; Gorski CJ; Kim S; Quinney S; Radovich M; Li L; Hall SD
    Pharmacogenomics J; 2009 Oct; 9(5):319-26. PubMed ID: 19506580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
    Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
    Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
    Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
    Yu KS; Cho JY; Jang IJ; Hong KS; Chung JY; Kim JR; Lim HS; Oh DS; Yi SY; Liu KH; Shin JG; Shin SG
    Clin Pharmacol Ther; 2004 Aug; 76(2):104-12. PubMed ID: 15289787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
    Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
    J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
    Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
    J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.